Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal bupivacaine (Pacira BioSciences, 0432ac)
- Development stage
- Unknown
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Percutaneous, Parenteral
01
Overview
Liposomal bupivacaine (Exparel) is an extended-release formulation of the local anesthetic bupivacaine, utilizing the DepoFoam multivesicular liposomal delivery system. Developed by Pacira BioSciences, it is designed to provide prolonged postsurgical analgesia for up to 72 hours by slowly releasing bupivacaine into the surgical site or near nerves. Bupivacaine acts by binding to and blocking voltage-gated sodium channels on the internal surface of nerve cell membranes, preventing the generation and conduction of nerve impulses. This mechanism effectively provides local anesthesia and reduces the need for systemic opioids. It is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for postsurgical regional analgesia.
- Brand names
- Exparel
- Other names
- bupivacaine liposomebupivacaine liposome injectable suspensionDepoBupivacaine
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on liposomal bupivacaine (Pacira BioSciences, 0432ac).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal bupivacaine (Pacira BioSciences, 0432ac).